Marsh McLennan (MRSH) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
19 Jan, 2026Executive summary
Achieved 6% GAAP revenue growth and 5% underlying revenue growth in Q3 2024, with strong execution in Risk & Insurance Services and Consulting.
Q3 net income was $747M, with diluted EPS up 3% to $1.51 and adjusted EPS up 4% to $1.63; nine-month net income was $3.3B.
Announced $7.75B acquisition of McGriff Insurance Services, expected to close by year-end, funded by cash and new debt, and expected to be modestly accretive to adjusted EPS in year one.
Year-to-date, nearly $10B committed to acquisitions, including McGriff and other strategic deals, marking the largest M&A year in company history.
Repurchased 4.3M shares for $900M year-to-date; quarterly dividend raised to $0.815 per share.
Financial highlights
Q3 consolidated revenue was $5.7B (+6%); nine-month revenue was $18.4B (+7%).
Q3 operating income was $1.1B (+11%); adjusted operating income was $1.2B (+12%).
Q3 adjusted EPS was $1.63, up 4% year-over-year, or 11% excluding a discrete tax benefit last year; nine-month adjusted EPS was $6.93, up 10%.
Q3 net income margin was 13.1%; nine-month net income margin was 17.8%.
Completed $300M in share repurchases in Q3; $900M YTD.
Outlook and guidance
Expect mid-single-digit or better underlying revenue growth, margin expansion, and strong adjusted EPS growth for full year 2024, assuming current macro conditions persist.
Integration of McGriff expected to enhance capabilities and growth; $500M deferred tax asset assumed.
Restructuring activities expected to total $650M in charges, with $540M incurred through Q3 2024; over $500M in savings anticipated, mostly by end of 2024.
Plan to pause share repurchases in Q4 due to the McGriff acquisition, but expect to maintain a balanced capital management approach in 2025.
Anticipate continued strong free cash flow growth aligned with earnings growth.
Latest events from Marsh McLennan
- 2025 revenue up 10%, adjusted EPS up 9%, and $2.0B in share repurchases.MRSH
Q4 202527 Feb 2026 - Q2 revenue up 6%, EPS up 10%, margin 29%, and dividend raised 15% amid robust growth.MRSH
Q2 20243 Feb 2026 - Strong 2024 growth, record acquisitions, and margin expansion set up a positive 2025 outlook.MRSH
Q4 20249 Jan 2026 - Q1 2025 revenue up 9%, adjusted EPS up 5%, with strong segment growth and capital returns.MRSH
Q1 202519 Dec 2025 - Strong 2024 results, robust governance, and key votes on directors, pay, auditor, and equity plan.MRSH
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, pay, auditor, and incentive plan, all board-backed.MRSH
Proxy Filing1 Dec 2025 - Q2 2025 delivered 12% revenue growth, 11% EPS gain, and a 10% dividend increase.MRSH
Q2 20255 Nov 2025 - Q3 revenue up 11%, adjusted EPS up 11%, Thrive targets $400M savings, rebranding to Marsh.MRSH
Q3 202520 Oct 2025